Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/12/2026

1. CRWV
2. SMCI
3. GAMI
4. LITE
5. ONON

6. SPY
7. CAVA
8. CSCO
9. USO
10. NTHI

Get Alerts MNPR Hot Sheet

Price: $114.90 +0.38%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference.

Presentation Details:

Date: October 6, 2022Time: 12:00 p.m. (ET)Location: The Yale Club, New York City, New York

https://www.roth.com/conferences/upcoming-conferences

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc. Investor Relations Kim R. Tsuchimoto Chief Financial Officer [email protected]

Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics